< Return to PAMED News

PA DOH Patient Advocacy Program Advisory: Increased Risk of Withdrawal Symptoms Associated with 7-hydroxymitragynine (7-OH) and Tianeptine

Last Updated

Sep 11, 2026, 10:28 AM

pamed-member-resource

Leave a comment
Newest on top Oldest on top
Load more comments
Login to be able to comment